EGFR Exon 20 Insertions: A Distinct Group in Lung Cancer

What They Are

Exon 20 of EGFR encodes part of the kinase domain just after the C-helix. Insertions here add one or more amino acids, most commonly between codons 762 and 774. Dozens of distinct insertions have been described.

They account for roughly 5 to 12 percent of EGFR-mutant non-small-cell lung cancer, making them the third most common category after exon 19 deletions and L858R.

Why They Behave Differently

Most exon 20 insertions activate the kinase by locking the C-helix in an active position without substantially enlarging the drug-binding pocket. Classical first- and second-generation EGFR inhibitors bind poorly as a result, so response rates are low.

One exception is the A763_Y764insFQEA insertion near the start of exon 20, which behaves more like a classical sensitising mutation.

Detection

Many exon 20 insertions are missed by PCR-based hotspot assays designed for exon 19 deletions and L858R. Next-generation sequencing that covers the full exon, and careful bioinformatic calling of insertions, gives better detection.

A negative result from a limited assay does not exclude an exon 20 insertion, so test breadth should be checked when clinical suspicion is high.

Targeted Options

Amivantamab, a bispecific antibody against EGFR and MET, is approved for EGFR exon 20 insertion non-small-cell lung cancer, initially after chemotherapy and now also in combination in the first-line setting. Mobocertinib, an oral inhibitor designed for exon 20 insertions, was approved and then withdrawn after a confirmatory trial did not meet its endpoint.

Other exon 20-directed inhibitors are in development. The A763_Y764insFQEA subtype may respond to standard EGFR inhibitors such as osimertinib.

Interpretation Notes

An EGFR exon 20 insertion report should specify the exact insertion, since a small number behave atypically and drug data are strongest for the common variants.

These mutations are generally mutually exclusive with classical EGFR mutations and with other lung-cancer drivers.

Key Takeaways

• ·EGFR exon 20 insertions are a diverse group that mostly resists classical EGFR inhibitors.
• ·They activate the kinase without opening the drug-binding pocket.
• ·PCR hotspot panels miss many; full-exon next-generation sequencing detects more.
• ·Amivantamab is approved; the exact insertion should be recorded (A763_Y764insFQEA is an exception).